絞り込み

16645

広告

Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled Trial.

著者 Thase ME , Parikh SV , Rothschild AJ , Dunlop BW , DeBattista C , Conway CR , Forester BP , Mondimore FM , Shelton RC , Macaluso M , Li J , Brown K , Jablonski MR , Greden JF
J Clin Psychiatry.2019 Oct 31 ; 80(6):.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (16view , 0users)

Full Text Sources

Medical

The objective of the Genomics Used to Improve DEpression Decisions (GUIDED) trial was to evaluate the utility of pharmacogenomic testing to improve outcomes among patients with major depressive disorder (MDD) who had not responded to at least 1 prior medication trial. The objective of the present analysis was to assess outcomes for the subset of patients expected to benefit from combinatorial pharmacogenomic testing because they were taking medications with predicted gene-drug interactions.
PMID: 31721487 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード